Biodesix, Inc. (BDSX)

Biodesix's stock was impacted by a one-for-twenty reverse stock split in September 2025, which led to a decrease in institutional shares. Despite a challenging prior year, the stock experienced a gain in the 30 days leading up to January 14, 2026. The company reported strong fourth-quarter and fiscal year 2025 results, with a significant revenue increase and positive Adjusted EBITDA, leading to an optimistic outlook for fiscal year 2026. Analyst sentiment has been positive, with upgrades and restated buy ratings, and insiders have shown confidence through share purchases.

Biodesix, Inc. experiences demand seasonality, anticipating a seasonal step down in average selling price and volume during the first quarter of the year due to historical trends and potential weather disruptions.

Biodesix, Inc. is a diagnostic solutions company focused on improving clinical care and outcomes for patients with lung disease and other cancers through data-driven diagnostic solutions. The company offers blood-based lung tests and lung cancer diagnosis tests to evaluate lung cancer risk, guide treatment pathways, identify tumor mutations, and assess the patient's immune system. Biodesix also provides development services to biopharmaceutical, life sciences, and research institutions.

Biodesix, Inc. is headquartered in Louisville, Colorado, and operates laboratories primarily within the United States.

Biodesix has maintained a reputation as a leading diagnostic solutions company focused on improving clinical care and patient outcomes, particularly in lung disease. Strategic partnerships enhance its development services and product pipeline. Analyst ratings generally reflect a positive outlook. Financial concerns, such as ongoing net losses and a significant cash burn rate, could indirectly influence overall perception.

Biodesix, Inc. has a notable institutional ownership presence, with several major institutional owners holding a significant number of shares. Matthew Strobeck is reported to own the most shares among individual investors. Insiders collectively own approximately 30.10% of the company's stock.